PMID- 31947962
OWN - NLM
STAT- MEDLINE
DCOM- 20200602
LR  - 20200602
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jan 4
TI  - Curcumin Can Decrease Tissue Inflammation and the Severity of HSV-2 Infection in 
      the Female Reproductive Mucosa.
LID - 10.3390/ijms21010337 [doi]
LID - 337
AB  - Herpes Simplex Virus Type 2 (HSV-2) is one of the most prevalent sexually 
      transmitted viruses and is a known risk factor for HIV acquisition in the Female 
      Genital Tract (FGT). Previously, we found that curcumin can block HSV-2 infection 
      and abrogate the production of inflammatory cytokines and chemokines by genital 
      epithelial cells in vitro. In this study, we investigated whether curcumin, 
      encapsulated in nanoparticles and delivered by various in vivo routes, could 
      minimize inflammation and prevent or reduce HSV-2 infection in the FGT. Female 
      mice were pre-treated with curcumin nanoparticles through oral, intraperitoneal 
      and intravaginal routes, and then exposed intravaginally to the tissue 
      inflammation stimulant CpG-oligodeoxynucleotide (ODN). Local intravaginal 
      delivery of curcumin nanoparticles, but not intraperitoneal or oral delivery, 
      reduced CpG-mediated inflammatory histopathology and decreased production of 
      pro-inflammatory cytokines Interleukin (IL)-6, Tumor Necrosis Factor Alpha 
      (TNF-alpha) and Monocyte Chemoattractant Protein-1 (MCP-1) in the FGT. However, 
      curcumin nanoparticles did not demonstrate anti-viral activity nor reduce tissue 
      pathology when administered prior to intravaginal HSV-2 infection. In an 
      alternative approach, intravaginal pre-treatment with crude curcumin or solid 
      dispersion formulations of curcumin demonstrated increased survival and delayed 
      pathology following HSV-2 infection. Our results suggest that curcumin 
      nanoparticle delivery in the vaginal tract could reduce local tissue 
      inflammation. The anti-inflammatory properties of curcumin delivered to the 
      vaginal tract could potentially reduce the severity of HSV-2 infection and 
      decrease the risk of HIV acquisition in the FGT of women.
FAU - Vitali, Danielle
AU  - Vitali D
AD  - Department of Pathology & Molecular Medicine and McMaster Immunology Research 
      Centre, McMaster University, Hamilton, ON L8S 4K1, Canada.
FAU - Bagri, Puja
AU  - Bagri P
AD  - Department of Pathology & Molecular Medicine and McMaster Immunology Research 
      Centre, McMaster University, Hamilton, ON L8S 4K1, Canada.
FAU - Wessels, Jocelyn M
AU  - Wessels JM
AD  - Department of Pathology & Molecular Medicine and McMaster Immunology Research 
      Centre, McMaster University, Hamilton, ON L8S 4K1, Canada.
FAU - Arora, Meenakshi
AU  - Arora M
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Texas A&M University, 
      College Station, TX 77843, USA.
FAU - Ganugula, Raghu
AU  - Ganugula R
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Texas A&M University, 
      College Station, TX 77843, USA.
FAU - Parikh, Ankit
AU  - Parikh A
AD  - School of Pharmacy and Medical Sciences, University of South Australia, Adelaide 
      5000, Australia.
FAU - Mandur, Talveer
AU  - Mandur T
AD  - Department of Pathology & Molecular Medicine and McMaster Immunology Research 
      Centre, McMaster University, Hamilton, ON L8S 4K1, Canada.
FAU - Felker, Allison
AU  - Felker A
AD  - Department of Pathology & Molecular Medicine and McMaster Immunology Research 
      Centre, McMaster University, Hamilton, ON L8S 4K1, Canada.
FAU - Garg, Sanjay
AU  - Garg S
AUID- ORCID: 0000-0001-7253-2629
AD  - School of Pharmacy and Medical Sciences, University of South Australia, Adelaide 
      5000, Australia.
FAU - Kumar, M N V Ravi
AU  - Kumar MNVR
AD  - Department of Pharmaceutical Sciences, College of Pharmacy, Texas A&M University, 
      College Station, TX 77843, USA.
FAU - Kaushic, Charu
AU  - Kaushic C
AUID- ORCID: 0000-0002-7088-2569
AD  - Department of Pathology & Molecular Medicine and McMaster Immunology Research 
      Centre, McMaster University, Hamilton, ON L8S 4K1, Canada.
LA  - eng
GR  - 126019/CAPMC/CIHR/Canada
GR  - 138657/CAPMC/CIHR/Canada
GR  - R01EY028169/NH/NIH HHS/United States
PT  - Journal Article
DEP - 20200104
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (CPG-oligonucleotide)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Drug Carriers)
RN  - 0 (Interleukin-6)
RN  - 0 (Oligodeoxyribonucleotides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - IT942ZTH98 (Curcumin)
SB  - IM
MH  - Administration, Intravaginal
MH  - Animals
MH  - Chemokine CCL2/metabolism
MH  - Curcumin/chemistry/*pharmacology/therapeutic use
MH  - Drug Carriers/chemistry
MH  - Epithelial Cells/cytology/metabolism/virology
MH  - Female
MH  - Genitalia, Female/cytology/metabolism
MH  - Herpes Simplex/*pathology/veterinary/virology
MH  - Herpesvirus 2, Human/physiology
MH  - Humans
MH  - Inflammation/chemically induced/*pathology/prevention & control
MH  - Interleukin-6/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Nanoparticles/chemistry
MH  - Oligodeoxyribonucleotides/toxicity
MH  - Severity of Illness Index
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Vagina/metabolism/pathology
PMC - PMC6982333
OTO - NOTNLM
OT  - CpG
OT  - HSV-2
OT  - curcumin
OT  - cytokine
OT  - herpes
OT  - inflammation
OT  - nanoparticles
OT  - pathology
COIS- The authors declare no conflict of interest.
EDAT- 2020/01/18 06:00
MHDA- 2020/06/03 06:00
PMCR- 2020/01/01
CRDT- 2020/01/18 06:00
PHST- 2019/12/02 00:00 [received]
PHST- 2019/12/24 00:00 [revised]
PHST- 2019/12/31 00:00 [accepted]
PHST- 2020/01/18 06:00 [entrez]
PHST- 2020/01/18 06:00 [pubmed]
PHST- 2020/06/03 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - ijms21010337 [pii]
AID - ijms-21-00337 [pii]
AID - 10.3390/ijms21010337 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Jan 4;21(1):337. doi: 10.3390/ijms21010337.